Navigation Links
Silence Therapeutics Patent Update
Date:7/30/2008

LONDON, July 30 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading European RNAi focused biotechnology company, announces that the US Patent and Trademark Office has indicated on its official website that patent application 10/633,630, Silence's core RNAi patent application, has been allowed. The Company will make a further announcement once the official information has been reviewed.

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading European RNAi focused biotechnology company. RNAi can selectively 'silence' genes linked to the onset of disease. RNAi is a Nobel Prize winning technology and one of the most promising areas of drug discovery and development today.

Silence Therapeutics has developed a platform of novel short interfering RNA ('siRNA') molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation. In addition, the Company has developed a proprietary systemic delivery system, AtuPLEX. This system enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.

Silence's lead internal product, Atu027, is a proprietary AtuRNAi molecule in preclinical development for systemic cancer indications. Atu027 has successfully completed single and repeat dose toxicology and geno-toxicology studies, as well as a 28-day toxicology study using multiple dosing regimens. Silence plans a regulatory filing in 2008 to commence clinical trials for Atu027.

In March 2008, Silence Therapeutics announced a collaboration with AstraZeneca (LSE: AZN) focused on the development of a range of novel delivery approaches for siRNA molecules. Under the terms of the agreement both Silence Therapeutics and AstraZeneca will be allow
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
2. Organizational Changes at Silence Therapeutics
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
5. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
6. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
7. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
8. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
9. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
10. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
11. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... and TORONTO , March 5, ... a clinical-stage company developing new therapeutics and molecular diagnostics ... that William G. Rice , Ph.D., Chairman, President ... 27th Annual ROTH Conference on Tuesday, March 10 th ... Carlton, Laguna Niguel, CA. Dr. ...
(Date:3/5/2015)... Ohio (PRWEB) March 05, 2015 ... Gold Development Partner located in Northeast Ohio, today announced ... e2b teknologies to support its upgrade to the latest ... the largest independent group practice of its kind in ... and large volume of transactions, so efficiency and data ...
(Date:3/4/2015)... 2015 In an article published and posted ... Health Security review the clinical aspects of diseases caused ... bioweapons. The article, "Clinical Management of Potential Bioterrorism-Related Conditions," ... of the New England Journal of Medicine . ... , and Tom Inglesby—review the clinical management of conditions ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report ... a characteristic that can be objectively measured and ... pathogenic processes as well as pharmacological responses to ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2Latest Clinical Information On Bioterrorism Threats 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3
... Annual Biotechnology Investor Conference, November 8, Features ... Small to Mid-cap Public Growth Companies Renowned Investment ... Stelios Papadopoulos, ... The Massachusetts Biotechnology,Council,s ninth annual MASS Opportunities Investor Conference, ...
... AACR press ... conference, ... biotechnology company discovering and developing the next wave of,antibody therapeutics, today ... an oral presentation on one of the six abstracts it,will present ...
... Varian Medical,Systems (NYSE: VAR ) ... market-leading,VariSeed(TM) brachytherapy seed planning software. VariSeed 8.0,incorporates ... of the,treatment. "The new features provide ... seeds in permanent seed implants," says Rebecca ...
Cached Biology Technology:2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 22007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies 3Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference 2Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference 3Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference 4Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 2Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 3
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... the portions of the heart damaged by a lack of ... avoid this scarring, which can harden the walls of the ... and eventually lead to heart failure. But new research from ... Medicine shows that interrupting this process can weaken heart function ...
... CAMDEN How the brain perceives color is one ... a stable perception of an object,s color as lighting conditions ... at RutgersCamden, has teamed up with psychologists from the University ... how this works. Allred conducted the research with ...
... This release is available in German . ... rails as far as they go. But nature also knows systems ... in a hamster wheel, a train caught up in such a ... Cluster of Excellence Nanosystems Initiative Munich have now succeeded in building ...
Cached Biology News:Scarring a necessary evil to prevent further damage after heart attack 2Rutgers-Camden researcher examines how the brain perceives shades of gray 2Rutgers-Camden researcher examines how the brain perceives shades of gray 3Perfect micro rings woven from muscle fibers 2Perfect micro rings woven from muscle fibers 3
Human ABCG2 MAb (Clone 5D3)...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
... Engineered with new technology incorporating the ... unsurpassed flexibility, the new Varian NMR ... spectrometer available today., ,The Varian NMR ... transmitter and receiver channel, providing pulse ...
Biology Products: